Last year, high-flying stocks decreased significantly while old, “boring”, cash flow generative businesses fared much better. Since starting this blog, the objective has always been to find cash generative companies with robust prospects available at a cheap valuation. Let’s look at some of the companies that have been mentioned on here:
- Fuchs Petrolub: Shortly after the initial mentioning of Fuchs on this blog, the company initiated a share buyback program and has been continuously buying back shares on the market. So far, the timing has been excellent – bravo, Fuchs! In October, the firm also reiterated its guidance and was able to pass through higher costs to a large degree.
- Altice USA: So far, this company has been the biggest losers since the initial mentioning of this stock on this blog. The elephant in the room is clearly the big debt load, followed by shrinking revenues. With a market cap of slightly above $2 billion, there is a lot of optionality in the company if things don’t go more downhill. Signs for change are there: a new CEO and the accelerated fiber rollout.
- Viatris/Organon: Both spin-offs have been actively working on their new strategies as standalone companies. Viatris closed its sale of biosimilars to Biocon and will continue to adjust its portfolio in the years to come while paying an attractive dividend. Both companies will only be subject to a future potential interest rate increase: Organon’s next larger maturities will be in the years 2028 and 2031 while Viatris’ debt profile is diversified in terms of maturity.
What can we expect from 2023? How should I know? What I know though is that the approach in finding overlooked, cheap stocks will remain ;)
With this, I wish all my readers a Happy New Year and stay tuned!